Inhibrx Biosciences, Inc.
INBX
$113.06
$0.200.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | 1,200.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | 1,200.00% |
| Cost of Revenue | 7.33% | -31.62% | -24.03% | -26.63% | -67.08% |
| Gross Profit | -13.98% | 31.62% | 23.80% | 26.63% | 68.95% |
| SG&A Expenses | 28.46% | -5.21% | -66.54% | -33.24% | -93.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.06% | -27.91% | -38.19% | -27.75% | -82.18% |
| Operating Income | -17.38% | 27.91% | 38.06% | 27.75% | 82.98% |
| Income Before Tax | -27.90% | 22.79% | 31.40% | 19.62% | -101.54% |
| Income Tax Expenses | 50.00% | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | -27.91% | 22.79% | 31.40% | 19.62% | -101.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.91% | 22.79% | 31.40% | 19.62% | -101.54% |
| EBIT | -17.38% | 27.91% | 38.06% | 27.75% | 82.98% |
| EBITDA | -18.33% | 28.03% | 38.34% | 27.82% | 83.34% |
| EPS Basic | -26.26% | 23.37% | 31.69% | 19.68% | -101.46% |
| Normalized Basic EPS | -26.27% | 23.37% | 31.69% | 19.68% | 83.44% |
| EPS Diluted | -26.26% | 23.37% | 31.73% | 19.72% | -101.48% |
| Normalized Diluted EPS | -26.27% | 23.37% | 31.69% | 19.68% | 83.22% |
| Average Basic Shares Outstanding | 1.30% | 0.76% | 0.42% | 0.06% | 5.81% |
| Average Diluted Shares Outstanding | 1.30% | 0.76% | 0.42% | 0.06% | 4.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |